Search results
Showing 316 to 330 of 1254 results for criteria
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Show all sections
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 17 September 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 26 August 2026
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
In development Reference number: GID-HTE10084 Expected publication date: 21 October 2026
In development Reference number: GID-HTG10878 Expected publication date: 21 October 2026
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
Micropressure therapy for refractory Ménière's disease (HTG285)
Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.
View recommendations for HTG285Show all sections
Sections for HTG285
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.